La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ResMed Gestione

Gestione criteri di controllo 3/4

ResMed's Il CEO è Mick Farrell, nominato in Mar2013, e ha un mandato di 11.42 anni. la retribuzione annua totale è $ 13.87M, composta da 8.1% di stipendio e 91.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.32% delle azioni della società, per un valore di MX$ 2.02B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.4 anni e 8.8 anni.

Informazioni chiave

Mick Farrell

Amministratore delegato

US$13.9m

Compenso totale

Percentuale dello stipendio del CEO	8.1%
Mandato del CEO	11.5yrs
Proprietà del CEO	0.3%
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	8.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mick Farrell rispetto agli utili di ResMed?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$958m
Dec 31 2023	n/a	n/a	US$890m
Sep 30 2023	n/a	n/a	US$907m
Jun 30 2023	US$14m	US$1m	US$898m
Mar 31 2023	n/a	n/a	US$863m
Dec 31 2022	n/a	n/a	US$809m
Sep 30 2022	n/a	n/a	US$786m
Jun 30 2022	US$12m	US$1m	US$779m
Mar 31 2022	n/a	n/a	US$779m
Dec 31 2021	n/a	n/a	US$522m
Sep 30 2021	n/a	n/a	US$500m
Jun 30 2021	US$10m	US$1m	US$475m
Mar 31 2021	n/a	n/a	US$457m
Dec 31 2020	n/a	n/a	US$699m
Sep 30 2020	n/a	n/a	US$680m
Jun 30 2020	US$10m	US$1m	US$622m
Mar 31 2020	n/a	n/a	US$513m
Dec 31 2019	n/a	n/a	US$455m
Sep 30 2019	n/a	n/a	US$419m
Jun 30 2019	US$10m	US$967k	US$405m
Mar 31 2019	n/a	n/a	US$446m
Dec 31 2018	n/a	n/a	US$450m
Sep 30 2018	n/a	n/a	US$335m
Jun 30 2018	US$9m	US$934k	US$316m

Compensazione vs Mercato: La retribuzione totale di Mick ($USD 13.87M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 6.09M ).

Compensazione vs guadagni: La retribuzione di Mick è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mick Farrell (52 yo)

11.5yrs

Mandato

US$13,868,641

Compensazione

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Farrell	CEO & Chairman	11.5yrs	US$13.87m	0.32% $ 2.2b
Peter Farrell	Founder	no data	US$680.27k	0.058% $ 404.0m
Brett Sandercock	Chief Financial Officer	18.7yrs	US$3.11m	0.066% $ 457.8m
Robert Douglas	Special Advisor	less than a year	US$6.67m	0.18% $ 1.3b
Kaushik Ghoshal	Chief Commercial Officer - SaaS	2.6yrs	US$3.31m	0.015% $ 103.0m
Alastair Robertson	Chief Information Officer	less than a year	Nessun dato	Nessun dato
Amy Wakeham	Chief Investor Relations Officer	1.4yrs	Nessun dato	Nessun dato
Michael Rider	Chief Legal Officer	1.2yrs	Nessun dato	0.0072% $ 49.7m
Jim Ellis	Chief Compliance Officer	6.7yrs	Nessun dato	Nessun dato
Yvonne-Katrin Pucknat	Chief Marketing Officer	less than a year	Nessun dato	Nessun dato
Vered Keisar	Chief People Officer	3.5yrs	Nessun dato	Nessun dato
Hemanth Reddy	Chief Strategy Officer	9.8yrs	Nessun dato	Nessun dato

2.6yrs

Durata media

60.5yo

Età media

Gestione esperta: Il team dirigenziale di RMD * è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Farrell	CEO & Chairman	11.5yrs	US$13.87m	0.32% $ 2.2b
Peter Farrell	Founder	35.3yrs	US$680.27k	0.058% $ 404.0m
Richard Sulpizio	Independent Director	19.1yrs	US$340.06k	0.010% $ 70.7m
Ronald Taylor	Lead Independent Director	19.7yrs	US$372.56k	0.014% $ 98.6m
Jan De Witte	Independent Non-Executive Director	5.3yrs	US$320.06k	0.0039% $ 27.2m
Harjit Gill	Independent Director	5.8yrs	US$320.06k	0.0049% $ 34.0m
Carol Burt	Independent Director	10.8yrs	US$360.06k	0.010% $ 70.5m
Karen Drexler	Independent Director	6.8yrs	US$320.06k	0.0052% $ 35.8m
Desney Tan	Independent Director	2.8yrs	US$320.06k	0.0014% $ 9.8m
John Hernandez	Independent Director	2.8yrs	US$320.06k	0.0014% $ 9.8m

8.8yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RMD * sono considerati esperti (durata media dell'incarico 8.8 anni).

ResMed Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold Mex$203m worth of stock

Resmed Inc. Announces Board Changes

Chief Financial Officer recently sold Mex$52m worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Recent updates

ResMed Elects Christopher DelOrefice to the Board

Chief Product Officer recently sold Mex$203m worth of stock

Fourth quarter dividend of US$0.53 announced

Full year 2024 earnings released: EPS: US$6.94 (vs US$6.12 in FY 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

ResMed Secures Significant Victory in Patent Fight Against New York University

ResMed Secures Significant Victory in Patent Fight Against New York University

Resmed Inc. Announces Board Changes

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 21, 2023

ResMed Inc. to Report Q4, 2023 Results on Aug 03, 2023

Chief Financial Officer recently sold Mex$52m worth of stock

ResMed Inc. Announces Executive Changes

ResMed Inc. Announces Executive Changes

Upcoming dividend of US$0.44 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.22 in 3Q 2022)

Independent Director recently sold Mex$2.5m worth of stock

Upcoming dividend of US$0.44 per share at 0.8% yield

Second quarter 2023 earnings released: EPS: US$1.53 (vs US$1.38 in 2Q 2022)

ResMed Inc. Declares Quarterly Dividend, Payable on March 16, 2023

ResMed Inc. to Report Q2, 2023 Results on Jan 26, 2023

Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 15, 2022

ResMed Inc. to Report Q1, 2023 Results on Oct 27, 2022

ResMed Inc., Annual General Meeting, Nov 16, 2022

ResMed Inc. Announces Cash Dividend for the Quarter of Fiscal Year 2022, Payable on September 22, 2022

ResMed Inc. (NYSE:RMD) acquired mementor DE GmbH.

ResMed Inc. to Report Q4, 2022 Results on Aug 11, 2022

ResMed Announces the Promotion of Lucile Blaise to President of Sleep & Respiratory Care, Effective July 1, 2022

ResMed Inc. (NYSE:RMD) agreed to acquire Medifox-Dan Dresden Gmbh for €950 million.

Investor sentiment deteriorated over the past week

ResMed Inc. Announces Management Changes

Upcoming dividend of US$0.42 per share

Third quarter 2022 earnings released: EPS: US$1.22 (vs US$0.54 loss in 3Q 2021)

ResMed Inc. to Report Q3, 2022 Results on Apr 28, 2022

ResMed Announces Executive Changes

Upcoming dividend of US$0.42 per share

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

ResMed Inc. Announces Ordinary Distribution for the Quarter Ended December 31, 2021, Payable on March 17, 2022

Upcoming dividend of US$0.42 per share

First quarter 2022 earnings released: EPS US$1.40 (vs US$1.23 in 1Q 2021)

Upcoming dividend of US$0.39 per share

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$1.13 profit in 3Q 2020)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 17, 2021

Lead Independent Director recently sold Mex$16m worth of stock

Second quarter 2021 earnings released: EPS US$1.24 (vs US$1.11 in 2Q 2020)

Revenue beats expectations

ResMed Inc.(NYSE:RMD) dropped from S&P 400 Health Care (Sector)

ResMed Inc. to Report Q2, 2021 Results on Jan 28, 2021

Upcoming Dividend of US$0.39 Per Share

First quarter earnings released

First-quarter earnings released: Revenue beats expectations

ResMed Inc. to Report Q1, 2021 Results on Oct 29, 2020

Full year earnings released - EPS Mex$4.31

Earnings released

ResMed Inc. to Report Q4, 2020 Results on Aug 05, 2020

ResMed Inc.(NYSE:RMD) dropped from Russell 1000 Dynamic Index

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato